Author: Kanekiyo, Masaru; Bu, Wei; Joyce, M. Gordon; Meng, Geng; Whittle, James R.R.; Baxa, Ulrich; Yamamoto, Takuya; Narpala, Sandeep; Todd, John-Paul; Rao, Srinivas S.; McDermott, Adrian B.; Koup, Richard A.; Rossmann, Michael G.; Mascola, John R.; Graham, Barney S.; Cohen, Jeffrey I.; Nabel, Gary J.
Title: Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site Cord-id: 43jz55qs Document date: 2015_8_1
ID: 43jz55qs
Snippet: Epstein-Barr virus (EBV) represents a major global health problem. Though it is associated with infectious mononucleosis and over 200,000 cancers annually worldwide, a vaccine is not available. The major target of immunity is EBV glycoprotein 350/220 (gp350) that mediates attachment to B cells through complement receptor 2 (CR2/CD21). Here, we created self-assembling nanoparticles that displayed different domains of gp350 in a symmetric array. By focusing presentation of the CR2-binding domain o
Document: Epstein-Barr virus (EBV) represents a major global health problem. Though it is associated with infectious mononucleosis and over 200,000 cancers annually worldwide, a vaccine is not available. The major target of immunity is EBV glycoprotein 350/220 (gp350) that mediates attachment to B cells through complement receptor 2 (CR2/CD21). Here, we created self-assembling nanoparticles that displayed different domains of gp350 in a symmetric array. By focusing presentation of the CR2-binding domain on nanoparticles, potent neutralizing antibodies were elicited in mice and non-human primates. The structurally designed nanoparticle vaccine improved vaccine-induced protection in a mouse model by targeting a functionally conserved site of vulnerability with 10- to 100-fold increased neutralization compared to soluble gp350. This rational approach to EBV vaccine design elicited potent neutralizing antibody responses by focusing on a conserved viral entry domain, a strategy that can be applied to other viruses.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adjuvant system: 1, 2
- acute respiratory syndrome and low affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory syndrome and low subunit: 1
- acute respiratory syndrome and luciferase immunoprecipitation system: 1
- acute respiratory syndrome and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute respiratory syndrome and lymphoproliferative disorder: 1
- acute respiratory syndrome and macaca fascicularis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and macaque model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- adjuvant response and lymph node: 1
- adjuvant system and lymph node: 1
Co phrase search for related documents, hyperlinks ordered by date